Last, knockdown of cGAS with shRNA in 3 primary MDS specimens consistently showed a marked reduction in caspase-1 cleavage (Figure 4, C–E), confirming that cGAS engagement of DNA licensed NLRP3 inflammasome activation in MDS. The gene discussed is NLRP3; the disease is myelodysplastic syndrome.